Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Nanomedicine
2013 Aug 01;96:758-66. doi: 10.1016/j.nano.2013.01.008.
Show Gene links
Show Anatomy links
Volatile fingerprints of cancer specific genetic mutations.
Peled N
,
Barash O
,
Tisch U
,
Ionescu R
,
Broza YY
,
Ilouze M
,
Mattei J
,
Bunn PA
,
Hirsch FR
,
Haick H
.
Abstract
We report on a new concept for profiling genetic mutations of (lung) cancer cells, based on the detection of patterns of volatile organic compounds (VOCs) emitted from cell membranes, using an array of nanomaterial-based sensors. In this in-vitro pilot study we have derived a volatile fingerprint assay for representative genetic mutations in cancer cells that are known to be associated with targeted cancer therapy. Five VOCs were associated with the studied oncogenes, using complementary chemical analysis, and were discussed in terms of possible metabolic pathways. The reported approach could lead to the development of novel methods for guiding treatments, so that patients could benefit from safer, more timely and effective interventions that improve survival and quality of life while avoiding unnecessary invasive procedures. Studying clinical samples (tissue/blood/breath) will be required as next step in order to determine whether this cell-line study can be translated into a clinically useful tool.
FROM THE CLINICAL EDITOR: In this novel study, a new concept for profiling genetic mutations of (lung) cancer cells is described, based on the detection of patterns of volatile organic compounds emitted from cell membranes, using an array of nano-gold based sensors.
Amal,
The scent fingerprint of hepatocarcinoma: in-vitro metastasis prediction with volatile organic compounds (VOCs).
2012, Pubmed
Amal,
The scent fingerprint of hepatocarcinoma: in-vitro metastasis prediction with volatile organic compounds (VOCs).
2012,
Pubmed
Amann,
Lung cancer biomarkers in exhaled breath.
2011,
Pubmed
Amann,
Breath analysis: the approach towards clinical applications.
2007,
Pubmed
Bajtarevic,
Noninvasive detection of lung cancer by analysis of exhaled breath.
2009,
Pubmed
Barash,
Classification of lung cancer histology by gold nanoparticle sensors.
2012,
Pubmed
Barash,
Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles.
2009,
Pubmed
Belonogov,
Changes in the content of protein and lipid oxidative modification products in tumor tissue at different stages of lung cancer.
2009,
Pubmed
Cappuzzo,
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
2007,
Pubmed
Doebele,
New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
2010,
Pubmed
Dovgolevsky,
Chemically sensitive resistors based on monolayer-capped cubic nanoparticles: towards configurable nanoporous sensors.
2009,
Pubmed
Einhorn,
Will we ever have personalized medicine for non-small cell lung cancer?
2006,
Pubmed
Hakim,
Volatile organic compounds of lung cancer and possible biochemical pathways.
2012,
Pubmed
Hakim,
Diagnosis of head-and-neck cancer from exhaled breath.
2011,
Pubmed
Horváth,
Exhaled biomarkers in lung cancer.
2009,
Pubmed
Ionescu,
Quantitative analysis of NO2 in the presence of CO using a single tungsten oxide semiconductor sensor and dynamic signal processing.
2002,
Pubmed
Jackman,
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
2006,
Pubmed
Kato,
Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
2010,
Pubmed
Kischkel,
Breath biomarkers for lung cancer detection and assessment of smoking related effects--confounding variables, influence of normalization and statistical algorithms.
2010,
Pubmed
Kneepkens,
The potential of the hydrocarbon breath test as a measure of lipid peroxidation.
1994,
Pubmed
Konvalina,
Effect of humidity on nanoparticle-based chemiresistors: a comparison between synthetic and real-world samples.
2012,
Pubmed
Mano,
Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
2008,
Pubmed
,
Echinobase
Merlo,
EGFR pathway in advanced non-small cell lung cancer.
2011,
Pubmed
Modak,
Breath biomarkers for personalized medicine.
2010,
Pubmed
O'Callaghan,
Treatment of pulmonary arterial hypertension with targeted therapies.
2011,
Pubmed
Patel,
ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors.
2008,
Pubmed
Peng,
Detecting simulated patterns of lung cancer biomarkers by random network of single-walled carbon nanotubes coated with nonpolymeric organic materials.
2008,
Pubmed
Peng,
Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors.
2010,
Pubmed
Peng,
Diagnosing lung cancer in exhaled breath using gold nanoparticles.
2009,
Pubmed
Pleasance,
A comprehensive catalogue of somatic mutations from a human cancer genome.
2010,
Pubmed
Poli,
Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS.
2010,
Pubmed
Poli,
Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study.
2005,
Pubmed
Shaw,
Targeting anaplastic lymphoma kinase in lung cancer.
2011,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Shedden,
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
2008,
Pubmed
Soda,
A mouse model for EML4-ALK-positive lung cancer.
2008,
Pubmed
Sponring,
Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells.
2010,
Pubmed
Unger,
A pause, progress, and reassessment in lung cancer screening.
2006,
Pubmed
Wong,
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
2009,
Pubmed
,
Echinobase
